Oncocyte (NASDAQ:IMDX) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of Oncocyte (NASDAQ:IMDX) from a hold rating to a sell rating in a research note released on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oncocyte in a research report on Wednesday, June 24th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $12.00.

Oncocyte Price Performance

IMDX opened at $4.32 on Friday. The business has a fifty day simple moving average of $5.08 and a 200 day simple moving average of $5.08. Oncocyte has a 1 year low of $2.33 and a 1 year high of $8.51. The company has a market capitalization of $141.35 million, a PE ratio of -2.90 and a beta of 1.79.

Oncocyte (NASDAQ:IMDX) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.23) earnings per share for the quarter. The business had revenue of $0.24 million during the quarter.

Oncocyte Company Profile

Oncocyte (NASDAQ:IMDX) is a molecular diagnostics company that develops and commercializes tests intended to improve cancer detection, risk stratification and treatment decision-making. The company focuses on creating assays that provide clinically actionable information to physicians managing patients with suspected or confirmed malignancies, with particular emphasis on tools that can help evaluate lung nodules and other oncology-related diagnostic challenges.

Oncocyte’s product and development efforts center on blood- and tissue-based molecular assays that analyze biomarkers and genomic signals to inform clinical workflows.